


Cite this: *RSC Adv.*, 2023, 13, 18651

Epsilon-poly-L-lysine conjugated erythromycin for enhanced antibiotic therapy†

Jie Yu,^a Danwei Cen,^b Yongcheng Chen,^c Hailan Zhao,^a Mengyue Xu,^a Sulan Wu,^a Shuo Wang,^{*b} Qiao Jin^{©c} and Ting Shen^{*d}

Antibiotic resistance is a big threat to public health. How to improve the therapeutic efficacy of conventional antibiotics is an effective way to address this issue. In order to enhance the antibacterial activity of conventional antibiotic erythromycin (EM), EM is conjugated to positively charged ϵ -poly-L-lysine (EPL) to obtain EPL modified EM (EPL-EM). The grafting ratio of EM can be calculated from the ^1H NMR spectrum. EPL-EM is stable in physiological environment, while EM can be readily released from EPL-EM upon incubating with esterase which can be secreted by most bacteria. Because of the presence of cationic EPL, EPL-EM showed much stronger antibacterial activity than free EM, with much lower minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). Moreover, compared to free EM, the development of drug resistance can be slowed down if EPL-EM is used, which can be ascribed to the reduction of EM dosage. Meanwhile, EPL-EM cannot induce hemolysis and cytotoxicity, which indicates that EPL-EM exhibits excellent biocompatibility. The design of EPL-EM with enhanced antibacterial activity and excellent biocompatibility provides an innovative way to combat antibiotic resistance.

Received 12th May 2023
Accepted 15th June 2023

DOI: 10.1039/d3ra03168c

rsc.li/rsc-advances

1. Introduction

Antibiotic resistance is one of the biggest threats to humans' life and health, which can affect anyone of all ages in any country.^{1–3} There are already some "superbugs" that are resistant to most of the antibiotics and other medications in the world, such as carbapenem-resistant *Enterobacteriaceae*, multidrug-resistant *Acinetobacter baumannii*, multidrug-resistant *Klebsiella pneumoniae*, and methicillin-resistant *Staphylococcus aureus* (MRSA). The World Health Organization (WHO) announced that we were in the post-antibiotic era in 2013.⁴ Based on a report from the WHO in 2017, about 700 000 people will be killed by antibiotic resistance, which will increase to 10 million by 2050 if new medical interventions are not developed.⁵ The overcome of antibiotic resistance was selected as one of the 125 scientific

questions of greatest concern in the world by Science Magazine in 2021. It is urgently needed to develop new strategies to inhibit or decelerate the development of antibiotic resistance.^{6–9}

There are already many strategies in combating antibiotic resistance.^{10–13} For example, we can use non-antibiotic strategies to treat bacterial infections.^{14,15} Photothermal therapy and photodynamic therapy are very effective in eliminating bacterial cells.^{16–20} Some transition metal (Ag, Cu, Zn, *etc.*) exhibit strong bacteriocidal capability and are very promising in sterilization.^{21–23} Antimicrobial peptides (AMPs) which have broad activity to directly kill bacterial cells are widely used in antibacterial applications.^{24–27} However, it is still very difficult for these non-antibiotic strategies in treating bacterial infections *in vivo*. On the other hand, the reduction of the dosage of antibiotics is also effective in inhibiting the development of antibiotic resistance.^{28,29} In order to achieve this goal, it is necessary to enhance the therapeutic efficacy of conventional antibiotics. Various antibiotic loaded nanoparticles were designed, which can enhance the therapeutic efficacy of conventional antibiotics by inhibiting degradation, improving biodistribution, enhancing biofilm penetration, enhancing drug–bacteria interaction, and so on.^{30–33} Chemical modification of conventional antibiotics is another effective way to improve the therapeutic efficacy. As a typical example, C-terminus guanidine modification of vancomycin was reported for enhanced antibacterial activity.³⁴ Polyamidoamine (PAMAM) dendrimer conjugated azithromycin was much more effective in preventing productive infections than free azithromycin.³⁵

^aCenter for Rehabilitation Medicine, Department of Ophthalmology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, China

^bFaculty of Pharmacy, Zhejiang Pharmaceutical University, Ningbo 315100, China. E-mail: wangs@zjpu.edu.cn

^cMOE Key Laboratory of Macromolecule Synthesis and Functionalization of Ministry of Education, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310058, China

^dEye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou, 310009, China. E-mail: medicat@zju.edu.cn

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3ra03168c>



Erythromycin (EM) is a widely used macrolide antibiotic, which exhibits strong inhibition ability against Gram-positive bacteria, including *Staphylococcus aureus* (*S. aureus*), *Streptococcus pyogenes*, *Streptococcus viridans*, *Enterococcus faecalis* (*E. faecalis*), and so on. However, the therapeutic efficacy of EM is always relatively poor in clinic. In order to improve the antibacterial activity of EM, ϵ -poly-L-lysine (EPL) conjugated EM (EPL-EM) was designed in this research. EPL is a cationic polypeptide with antibacterial activity. EPL can interact with the outer membrane of bacteria and lead to a permeabilization of bacterial membranes. Due to the presence of EPL, EPL-EM is expected to adhere to bacterial cells by electrostatic interaction and enhance the permeabilization of bacterial membranes, which might improve the antibacterial activity of EM. The dosage of EM can hence be reduced, which is beneficial for the deceleration of the development of antibiotic resistance.

2. Experimental section

2.1 Materials

Erythromycin (EM, Dalian Meilun Biotechnology Co., Ltd), ϵ -poly-L-lysine (EPL, M_w 3500–5000, Dalian Meilun Biotechnology Co., Ltd), succinic anhydride (Aladdin), esterase from porcine liver (Sigma-Aldrich), 1-ethyl-3-(3'-dimethylaminopropyl) carbodiimide hydrochloride (EDC, Sigma-Aldrich), and *N*-hydroxysuccinimide (NHS, Energy Chemical) were used as received. Milli-Qwater (18.2 MX cm^{-1}) was obtained using a Millipore Milli-Q Academic Water Purification System. Cell counting kit 8 (CCK-8) was purchased from Beyotime Biotechnology. *S. aureus* and *E. faecalis* were purchased from Guangdong culture collection center for all bacterial experiments. All other reagents were used as received without further purification.

2.2 Synthesis of succinic acid modified EM (EM-COOH)

EM-COOH was synthesized according to a reference with small modification by the reaction of EM and succinic anhydride.³⁶ Briefly, 1 g (1.362 mmol) of AZM was added dissolved in 20 mL of *N,N*-dimethylformamide (DMF). 136.2 mg (1.362 mmol) of succinic anhydride and 300 μL of triethylamine (TEA) were added. The reaction mixture was stirred for 24 h. DMF was then removed under reduced pressure. The resulting crude product was purified by column chromatography using methanol: ethyl acetate: petroleum ether (1 : 2 : 1) as eluent. Yield: 42%.

2.3 Synthesis of EPL conjugated EM (EPL-EM)

To a stirred solution of EM-COOH (83.3 mg, 0.1 mmol) in 8 mL of DMSO and 2 mL of H_2O , EDC (15.5 mg, 0.1 mmol) and NHS (11.05 mg, 0.1 mmol) were added to the reaction mixture. After 1 hour of stirring, 128 mg of EPL was added. The mixture was stirred at room temperature for 48 h. The reaction mixture was purified by dialysis using dialysis membrane (MWCO 1000 Da) with DMSO/ H_2O (8 : 2) for 48 h and Milli-Q water for another 48 h. The product was then freeze-dried and stored at 4 °C. Yield: 53%. The grafting ratio of EM in EPL-EM could be calculated based on the ^1H NMR spectrum of EPL-EM. The molecular weight of EPL was already known, which could be

used to calculate the polymerization degree of EPL. Therefore, the number of EM molecules conjugated to one EPL chain could be easily calculated.

2.4 In vitro drug release

In order to study esterase-responsive release of EM, 2 mL of EPL-EM (1 mg mL^{-1}) in phosphate-buffered saline (PBS) containing esterase was added into a dialysis bag. EPL-EM in PBS without esterase was used as a control. The dialysis bag was then immersed in a prepared tube. The tube was put in a thermostated incubator at 37 °C with constant shaking (100 rpm). 0.5 mL of solution was taken out at different time intervals and replaced with fresh PBS. The concentration of released EM was detected by HPLC.

2.5 Determination of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC)

The MIC values of EPL-EM and free EM were determined by a standard broth microdilution method. *S. aureus* or *E. faecalis* at a concentration of $5 \times 10^5 \text{ CFU mL}^{-1}$ was incubated with different concentrations of EPL-EM and free EM (2-fold dilution, from 0.5 to 32 $\mu\text{g mL}^{-1}$) in 96-well plates for 8 hours. After incubation, the MIC was read as the lowest antibiotic concentration completely inhibiting bacterial growth upon absorbance measurement by OD value, which was judged by lack of turbidity. The minimum bactericidal concentration (MBC) is the minimum concentration of an antibacterial agent that leads to 99.9% reduction of bacterial cells from initial bacterial inoculum. Culture wells with no visible turbidity were further sub-cultured for MBC determination. The solution from these wells were dropped on agar plates and incubated to determine MBC values. The MIC and MBC of EPL was measured similar to that of EPL-EM. The highest concentration of EPL used in this experiment was 256 $\mu\text{g mL}^{-1}$.

2.6 In vitro bactericidal activity of EPL-EM

The bactericidal activity of EPL-EM and free EM was evaluated by standard plate counting assays. At first, 100 μL PBS, EPL, free EM, or EPL-EM with 2 $\mu\text{g mL}^{-1}$, 4 $\mu\text{g mL}^{-1}$, 8 $\mu\text{g mL}^{-1}$, 16 $\mu\text{g mL}^{-1}$ (2-fold dilution, equivalent to PMB) were added into the 100 μL *S. aureus* or *E. faecalis* in 96-well plates and incubated for 8 h. The suspensions were then serially diluted with sterile PBS and living bacteria were counted by plate counting method on the tryptone soy agar (TSA) plates.

2.7 Antibiotic resistance evaluation

The occurrence of antibiotic resistance was evaluated by determining MIC after successive incubating of *S. aureus* with EM. After incubating *S. aureus* with EPL-EM or EM, the MIC value against *S. aureus* (passage 0) was determined by a standard MIC test method. *S. aureus* bacterial cells were then treated with EPL-EM or EM at the concentration of 1/2 MIC. The survived bacterial cells were collected and designated as passage 1. The MIC of EPL-EM or EM against *S. aureus* (passage 1) was determined again. *S. aureus* bacterial cells were again treated with EPL-EM or EM at the concentration of 1/2 MIC (passage 1). The survived bacterial cells were collected and



designated as passage 2. These operations were repeated for 10 successive passages. The MIC values of EPL-EM or EM against *S. aureus* at each passage were recorded, which was used to evaluate the development of antibiotic resistance.

2.8 Hemolysis evaluation

Rabbit red blood cells (RBCs) were used for hemolysis assay of EPL-EM. 100 μ L whole blood was centrifuged at 1500 rpm for 5 min to collect RBCs. The obtained RBCs were washed and re-suspended in 2 mL PBS to prepare 5% v/v RBCs suspension. 100 μ L RBCs suspension was mixed with EPL-EM (5, 10, 25, 50 μ g mL⁻¹). After 1 h incubation at 37 °C, the mixture was centrifuged at 1500 rpm for 5 min. The absorbance at 576 nm was detected using a microplate reader. PBS was used as negative control. 0.5% Triton X-100 was taken as full hemolysis. The percentage of hemolysis was calculated through eqn (1)

$$\text{Hemolysis ratio(\%)} = \frac{A_M - A_N}{A_P - A_N} \quad (1)$$

where A_M is the absorbance of EPL-EM group, A_N is the absorbance of PBS group, and A_P is the absorbance of Triton X-100 group.

2.9 In vitro cytotoxicity evaluation

The cytotoxicity of EPL-EM was evaluated by a standard CCK-8 assay. Human corneal epithelial cells (HCE-T) or mouse fibroblast cells (L929) were cultured in 96-well plates at a density of 10 000 cells per well. After 24 h incubation, the culture medium was replaced with EPL-EM (5, 10, 25, 50 μ g mL⁻¹) in fresh medium and incubated for another 24 h. The medium was then replaced with fresh medium containing CCK-8 (10%) for 1 h. Finally, the viability of cells was detected by a microplate Bio-Rad reader at 450 nm. Data were presented as mean $\pm$ standard deviation (SD) ($n = 4$).

2.10 Characterizations

¹H NMR and ¹³C NMR spectra were recorded on a Bruker DMX500 spectrometer. The mass spectra were recorded on a Bruker Esquire 3000 plus ion trap mass spectrometer equipped with an ESI source. The concentration of EM was determined by HPLC using Agilent 1200. The mobile phase was: acetonitrile: 0.4 M NH₄H₂PO₄ = 1 : 2. The microplate reader we used was Bio-Rad PR 4100 microplate reader.

2.11 Statistical analysis


Data were expressed as mean $\pm$ SD and the significant difference was determined by Student's *t*-test. no significance: n.s., **P* < 0.05, ***P* < 0.01, ****P* < 0.001.

3. Results and discussion

3.1 Synthesis of EPL conjugated EM (EPL-EM)

In order to synthesize EPL-EM, carboxylated EM (EM-COOH) was firstly obtained by reacting EM with succinic anhydride (Scheme 1). The successful synthesis of EM-COOH was

confirmed by ¹H NMR, ¹³C NMR, and ESI-MS. The appearance of a peak at δ 2.73–2.80 in Fig. S1† could be ascribed to –CH₂– next to the carboxyl group of EM-COOH in ¹H NMR. Meanwhile, two peaks (δ 174.0, δ 175.4) assigned to the carbonyl group were observed in ¹³C NMR of EM-COOH (Fig. S2†). The ESI-MS result in Fig. S3† was consistent with the theoretical molecular weight of EM-COOH. All these results proved the successful synthesis of EM-COOH. EPL-EM was then prepared after conjugating EM-COOH to EPL by the amidation reaction. The ¹H NMR spectrum of EPL-EM was shown in Fig. 1. The grafting ratio of EM in EPL-EM was calculated to be 8.1% based on the ¹H NMR spectrum of EPL-EM. Therefore, the loading content of EM in EPL-EM was 31.5%. The molecular weight of EPL we used was in the range of 3500 to 5000. Due to the relatively high molecular weight of EM (M_w 734), 2 to 3 EM molecules in average were conjugated to one EPL chain. It should be noted that EM cannot be dissolved in water. High grafting ratio of EM might induce the precipitation of EPL-EM in aqueous solution. Therefore, the grafting ratio of EM was kept relatively low in this research.



Scheme 1 Schematic illustration of the synthetic route of EPL-EM.




Fig. 1 The ¹H NMR spectrum of EPL-EM. DMSO-*d*₆ was used as the solvent.



The effective drug release is a critical step for prodrugs. EM was conjugated to EPL-EM *via* an esterase-sensitive ester bond (Scheme 2). The esterase can be secreted by most of bacterial strains. Therefore, the release of EM from EPL-EM was investigated in the presence of esterase by high performance liquid chromatography (HPLC). As shown in Fig. 2, EPL-EM exhibited outstanding stability in PBS without drug leakage. However, EM could be effectively released from EPL-EM in the presence of esterase. More than 60% of EM was released after incubating with esterase for 6 h, which could further increase to 90% upon prolonging incubating time to 24 h. Therefore, EPL-EM was stable in physiological environment, while EM could be readily released in bacterial infected sites.

3.2 *In vitro* antibacterial activity evaluation


After successful synthesis of EPL-EM, the antibacterial activity of EPL-EM was evaluated using free EM as control. Since EM is mainly used to treat Gram-positive bacterial infections in clinic, the Gram-positive bacterial strains including *S. aureus* and *E. faecalis* were used as model strains. Firstly, the minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of EPL-EM (EM equivalent) were determined. As shown in Table 1, the MIC of EPL-EM against *S. aureus* was 1 $\mu\text{g mL}^{-1}$ (EM equivalent), which was lower than

Table 1 The MIC and MBC of EM, EPL-EM, and EPL against different bacterial stains, including *S. aureus* and *E. faecalis*

Bactericidal agents	MIC ($\mu\text{g mL}^{-1}$)		MBC ($\mu\text{g mL}^{-1}$)	
	<i>S. aureus</i>	<i>E. faecalis</i>	<i>S. aureus</i>	<i>E. faecalis</i>
EM	2	4	16	16
EPL-EM (EM equivalent)	1	1	4	8
EPL	>256	>256	>256	>256

that of free EM (2 $\mu\text{g mL}^{-1}$). Meanwhile, the MIC of EPL-EM (1 $\mu\text{g mL}^{-1}$) against *E. faecalis* was also lower than free EM (4 $\mu\text{g mL}^{-1}$). Similarly, the MBC of EPL-EM against *S. aureus* and *E. faecalis* were 4 $\mu\text{g mL}^{-1}$ and 8 $\mu\text{g mL}^{-1}$, respectively, which were lower than that of free EM. However, the MIC and MBC of EPL against *S. aureus* and *E. faecalis* were higher than 256 $\mu\text{g mL}^{-1}$, which implied relatively low antibacterial activity.

The bactericidal activity of EPL-EM was further evaluated by the standard plates counting assay. EPL-EM with different concentrations (2, 4, 8, and 16 $\mu\text{g mL}^{-1}$ EM equivalent) were incubated with $\sim 10^8$ colony forming units (CFU) *S. aureus* or *E. faecalis* for 8 h. The residual live bacterial cells were evaluated by the plates counting assay. As depicted in Fig. 3, EPL-EM exhibited stronger antibacterial activity than free EM against *S. aureus*. Specifically, EPL-EM and free EM at 16 $\mu\text{g mL}^{-1}$ (EM equivalent) could lead to 3.8 and 2.7 orders of magnitude reduction of *S. aureus* colonies, respectively. EPL didn't exhibit obvious antibacterial activity due to the very low incubation concentration (35 $\mu\text{g mL}^{-1}$). Similarly, EPL-EM and free EM at 16 $\mu\text{g mL}^{-1}$ (EM equivalent) resulted in 4.6 and 3.6 orders of magnitude reduction of *E. faecalis* colonies, respectively (Fig. 4). Therefore, the conjugation of EM to EPL could significantly increase the antibacterial activity of EM. EPL-EM is a positively charged polymer and can adhere to negatively charged bacterial cells, which can lead to the accumulation of EM around bacterial cells. In this case, the local concentration of EM might be very high compared with free EM. Meanwhile, EPL itself is a cationic polypeptide with antibacterial



Scheme 2 Schematic illustration of esterase-responsive release of EM from EPL-EM.




Fig. 2 The release of EM from EPL-EM in PBS with or without esterase ($n = 3$).




Fig. 3 The *in vitro* antibacterial capability against *S. aureus* was evaluated by the standard plates counting assay. *S. aureus* was incubated with different concentrations of EPL, EM, or EPL-EM for 8 h ($n = 4$). Statistical analysis was conducted by the *t*-test; p value: $p < 0.05$, *; $p < 0.01$, **; $p < 0.001$, ***.






Fig. 4 The *in vitro* antibacterial capability against *E. faecalis* was evaluated the standard plates counting assay. *E. faecalis* was incubated with different concentrations of EPL, EM, or EPL-EM for 8 h ($n = 4$). Statistical analysis was conducted by the *t*-test; p value: $p < 0.05$, *; $p < 0.01$, **; $p < 0.001$, ***.

activity. Therefore, EPL-EM showed much stronger antibacterial activity than free EM.

As discussed above, EPL-EM showed much stronger antibacterial activity than free EM against planktonic bacteria. The biofilm-associated infection is a great challenge in clinic. Since EM was conjugated to positively charged EPL, the relatively large molecular and positive charge may inhibit the penetration of EPL-EM into bacterial biofilms, which may influence the therapeutic efficacy of biofilm-associated infections. The antibiofilm effect of EPL-EM will be investigated in future.

3.3 Reduced antibiotic resistance by EPL-EM

Although EM is a widely used antibiotic in clinic, the serious EM resistance is a critical issue. By conjugating EM to EPL, the antibacterial capability of EM was significantly improved. Therefore, compared to free EM, the dosage of EM could be remarkably reduced in the form of EPL-EM because of the enhanced antibacterial capability. In this case, it is very interesting to see if EPL-EM can reduce the occurrence of resistance compared with free




Fig. 5 Resistance development of *S. aureus* after continuous exposure toward EPL-EM or free EM at the concentration of half MIC for 10 passages ($n = 3$).

EM. *S. aureus* bacterial cells were serially incubated with a sublethal concentration of EPL-EM or free EM. The MIC values were determined after each passage in the whole procedure. As shown in Fig. 5, the MIC of free EM at passage 10 was 10.6-fold as that of passage 0. In contrast, the MIC of EPL-EM at passage 10 was 4.7-fold as that of passage 0. Therefore, compared to free EM, EPL-EM could reduce the occurrence of EM resistance.




Fig. 6 Hemolysis of mouse red blood cells after incubated with different concentrations of EPL-EM. Triton X-100 was used as a positive control ($n = 3$).




Fig. 7 The cell viability of (A) L929 and (B) HCE-T after incubating with different concentration of EPL-EM for 24 h ($n = 4$).



3.4 Biocompatibility evaluation

After confirmed the excellent antibacterial activity of EPL-EM, the biocompatibility of EPL-EM was further evaluated. At First, the hemolytic toxicity of EPL-EM was investigated by incubating EPL-EM with RBCs. As shown in Fig. 6, EPL-EM cannot induce obvious hemolysis when the polymer concentration was $50 \mu\text{g mL}^{-1}$, which implied excellent hemocompatibility of EPL-EM. The cytotoxicity of EPL-EM was further studied by a CCK-8 assay. Human corneal epithelial cells (HCE-T) and mouse fibroblast cells (L929) were used as model cells. After incubating EPL-EM (5, 10, 25, $50 \mu\text{g mL}^{-1}$) with HCE-T cells or L929 cells for 24 h, the cell viability was higher than 95%, which implied that EPL-EM exhibited excellent cytocompatibility (Fig. 7). Therefore, EPL-EM maintained outstanding biocompatibility after EM was conjugated with EPL, which was extremely important for practical applications.

4. Conclusions

In summary, EPL conjugated EM was successfully synthesized by the amidation reaction between EPL and EM-COOH. The grafting ratio of EM in EPL-EM was 8.1% determined by ^1H NMR. EPL-EM maintained stable in physiological environment without drug leakage. However, the release of EM from EPL-EM was significantly accelerated in the presence of esterase, which was overexpressed by most bacterial strains. The MIC values of EPL-EM (EM equivalent) against *S. aureus* and *E. faecalis* were both $1 \mu\text{g mL}^{-1}$, which was much lower than that of free EM. Similarly, the MBC of EPL-EM against *S. aureus* and *E. faecalis* was also lower than that of free EM. EPL-EM exhibited much stronger antibacterial activity against Gram-positive bacteria than free EM. Due to the excellent antibacterial activity of EPL-EM, much fewer dosage of EPL-EM could be used in antibacterial applications. Compared to free EM, the development of resistance could be slowed down if EPL-EM was used. Meanwhile, EPL-EM could not induce hemolysis and cytotoxicity, exhibiting outstanding biocompatibility. This research provides an innovative strategy to improve the antibacterial activity of EM while not bring in hemolysis and cytotoxicity, showing great potential in antibacterial applications.

Author contributions

Jie Yu: methodology, investigation, validation, writing – original draft; Danwei Cen: validation, formal analysis, writing – review & editing; Yongcheng Chen: investigation, visualization; Hailan Zhao: software, visualization; Mengyue Xu: software; Sulan Wu: data curation; Shuo Wang: supervision, project administration, writing – review & editing; Qiao Jin: project administration, supervision; Ting Shen: conceptualization, supervision, project administration, funding acquisition, writing – review & editing.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Financial support from General research program of Zhejiang Provincial Health Commission (2021KY076) is gratefully acknowledged.

References

- 1 D. G. J. Larsson and C.-F. Flach, *Nat. Rev. Microbiol.*, 2022, **20**, 257–269.
- 2 C. Nathan and O. Cars, *N. Engl. J. Med.*, 2014, **371**, 1761–1763.
- 3 R. Laxminarayan, D. Sridhar, M. Blaser, M. Wang and M. Woolhouse, *Science*, 2016, **353**, 874–875.
- 4 M. McKenna, *Nature*, 2013, **499**, 394–396.
- 5 M. E. A. de Kraker, A. J. Stewardson and S. Harbarth, *PLoS Med.*, 2016, **13**, e1002184.
- 6 Y. Chen, Y. Huang and Q. Jin, *Macromol. Chem. Phys.*, 2022, **223**, 2100440.
- 7 C. Liu, Z. Yang, X. Song, Y. Qian, H. Huo, J. He, J. Zhang, Z. Zhang, M. Shi, J. Pang, B. Zhang and W. Tian, *Supramol. Mater.*, 2022, **1**, 100014.
- 8 L. Zou, X. Li, Y. Huang, C. Wang, Y. Fang, J. Zhao, Q. Jin and J. Ji, *Nano Today*, 2023, **50**, 101828.
- 9 D. C. Angst, B. Tepekule, L. Sun, B. Bogos and S. Bonhoeffer, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**, e2023467118.
- 10 D. Chinemerem Nwobodo, M. C. Ugwu, C. Oliselo Anie, M. T. S. Al-Ouqaili, J. Chinedu Ikem, U. Victor Chigozie and M. Saki, *J. Clin. Lab. Anal.*, 2022, **36**, e24655.
- 11 J. Murugaiyan, P. A. Kumar, G. S. Rao, K. Iskandar, S. Hawser, J. P. Hays, Y. Mohsen, S. Adukkadukkam, W. A. Awuah, R. A. M. Jose, *et al.*, *Antibiotics*, 2022, **11**, 200.
- 12 S. Chandra, P. Dutta and K. Biswas, *ACS Nano*, 2022, **16**, 7–14.
- 13 Y. Jia, J. Zhang, Y. Zhao, R. Dong, H. Wang and X. Jiang, *Chem. Commun.*, 2022, **58**, 10544–10547.
- 14 A. Mobed, M. Hasanazadeh and F. Seidi, *RSC Adv.*, 2021, **11**, 34688–34698.
- 15 X. Chen, H. Han, Z. Tang, Q. Jin and J. Ji, *Adv. Healthcare Mater.*, 2021, **10**, 2100736.
- 16 Y. Wang, C. Zhang, H. Zhang, L. Feng and L. Liu, *Chin. Chem. Lett.*, 2022, **33**, 4605–4609.
- 17 X. Li, J. Man, H. Hu, J. Ye and Q. Jin, *Colloid Interface Sci. Commun.*, 2022, **47**, 100598.
- 18 Y. Huang, Q. Gao, X. Li, Y. Gao, H. Han, Q. Jin, K. Yao and J. Ji, *Nano Res.*, 2020, **13**, 2340–2350.
- 19 Y. Ren, H. Liu, X. Liu, Y. Zheng, Z. Li, C. Li, K. W. K. Yeung, S. Zhu, Y. Liang, Z. Cui, *et al.*, *Cell Rep. Phys. Sci.*, 2020, **1**, 100245.
- 20 O. A. Yeshchenko, N. V. Kutsevol, A. V. Tomchuk, P. S. Khort, P. A. Virych, V. A. Chumachenko, Y. I. Kuziv, A. P. Naumenko and A. I. Marinin, *RSC Adv.*, 2022, **12**, 11–23.
- 21 Y. Huang, Q. Gao, C. Li, X. Chen, X. Li, Y. He, Q. Jin and J. Ji, *Adv. Funct. Mater.*, 2022, **32**, 2109011.
- 22 S. Chernousova and M. Eppele, *Angew. Chem., Int. Ed.*, 2013, **52**, 1636–1653.
- 23 T. Bai, K. Zhao, Z. Lu, X. Liu, Z. Lin, M. Cheng, Z. Li, D. Zhu and L. Zhang, *Chin. Chem. Lett.*, 2021, **32**, 1051–1054.



- 24 S. Wang, Y. Yu, H. Li, Y. Huang, J. Wang, Q. Jin and J. Ji, *J. Polym. Sci.*, 2022, **60**, 2289–2297.
- 25 S. Nayab, M. A. Aslam, S. ur Rahman, Z. U. D. Sindhu, S. Sajid, N. Zafar, M. Razaq, R. Kanwar and Amanullah, *Int. J. Pept. Res. Ther.*, 2022, **28**, 46.
- 26 M. D. T. Torres, J. Cao, O. L. Franco, T. K. Lu and C. de la Fuente-Nunez, *ACS Nano*, 2021, **15**, 2143–2164.
- 27 Q. Wang, Y. Xu and J. Hu, *RSC Adv.*, 2022, **12**, 14485–14491.
- 28 Y. Gao, J. Wang, M. Chai, X. Li, Y. Deng, Q. Jin and J. Ji, *ACS Nano*, 2020, **14**, 5686–5699.
- 29 N. Osman, N. Devnarain, C. A. Omolo, V. Fasiku, Y. Jaglal and T. Govender, *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.*, 2022, **14**, e1754.
- 30 S. Wang, Y. Gao, Q. Jin and J. Ji, *Biomater. Sci.*, 2020, **8**, 6825–6839.
- 31 W. Gao, Y. Chen, Y. Zhang, Q. Zhang and L. Zhang, *Adv. Drug Delivery Rev.*, 2018, **127**, 46–57.
- 32 E. Porges, D. Jenner, A. W. Taylor, J. S. P. Harrison, A. De Grazia, A. R. Hailes, K. M. Wright, A. O. Whelan, I. H. Norville, J. L. Prior, *et al.*, *ACS Nano*, 2021, **15**, 19284–19297.
- 33 K. Deng, Y. Li, X. Liang, C. Shen, Z. Zeng and X. Xu, *Chin. Chem. Lett.*, 2022, **33**, 1619–1622.
- 34 Z.-C. Wu, M. D. Cameron and D. L. Boger, *ACS Infect. Dis.*, 2020, **6**, 2169–2180.
- 35 M. K. Mishra, K. Kotta, M. Hali, S. Wykes, H. C. Gerard, A. P. Hudson, J. A. Whittum-Hudson and R. M. Kannan, *Nanomedicine*, 2011, **7**, 935–944.
- 36 A. Bosnjakovic, M. K. Mishra, W. Ren, Y. E. Kurtoglu, T. Shi, D. Fan and R. M. Kannan, *Nanomedicine*, 2011, **7**, 284–294.

